The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer.
 
Debra A. Patt
Employment - McKesson; MedNax (I); Texas Oncology
Leadership - McKesson; Mednax (I); Texas Oncology
Stock and Other Ownership Interests - Mednax (I)
Consulting or Advisory Role - AstraZeneca; Pfizer; Roche
Research Funding - Eisai (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - McKesson
 
Xianchen Liu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Benjamin Li
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Lynn McRoy
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Rachel M. Layman
Consulting or Advisory Role - GE Healthcare (I); Genomic Health; Lilly; Novartis; Pfizer; Siemens (I)
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Zentalis (Inst)
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Bayer; Bioarray Therapeutics; bioTheranostics; Celgene; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; Genomic Health; Immunomedics; Lilly; Merck; Myriad Pharmaceuticals; NanoString Technologies; Novartis; Pfizer; Puma Biotechnology; Seagen